

## Full Paper

**Augmentation of  $\alpha_1$ -Adrenoceptor-Mediated Contraction by Warming Without Increased Phosphorylation of Myosin in Rat Caudal Arterial Smooth Muscle**Mitsuo Mita<sup>1,\*</sup>, Michael P. Walsh<sup>2</sup>, and Masaki Saito<sup>1</sup><sup>1</sup>Department of Pharmacodynamics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan<sup>2</sup>Smooth Muscle Research Group and Department of Biochemistry & Molecular Biology, University of Calgary, Alberta T2N 4N1, Canada

Received February 23, 2005; Accepted July 19, 2005

**Abstract.** We previously reported the relationship between  $\alpha_1$ -adrenoceptor-mediated contraction and phosphorylation of 20-kDa myosin light chain (LC<sub>20</sub>) in de-endothelialized rat caudal arterial smooth muscle at room temperature (Mita M, Walsh MP. *Biochem J.* 1997;327:669–674). We now describe the effect of increasing the temperature to 37°C on this relationship. The EC<sub>50</sub> value (76.6 ± 18.2 nM) for cirazoline ( $\alpha_1$ -adrenergic agonist)-induced contraction of the strips at room temperature (23°C) was significantly greater than that (14.5 ± 1.9 nM) at 37°C. The initial rate of the contraction to a sub-maximal concentration of cirazoline (0.3 μM) was similar at the two temperatures. However, cirazoline-induced maximal force at 37°C was approximately 1.8 times that at room temperature. LC<sub>20</sub> phosphorylation in response to cirazoline at room temperature and 37°C closely matched the time courses of contraction, but values were not significantly different at the two temperatures: resting phosphorylation levels were 0.09 ± 0.04 mol P<sub>i</sub>/mol LC<sub>20</sub> at 37°C and 0.22 ± 0.06 mol P<sub>i</sub>/mol LC<sub>20</sub> at room temperature; maximal cirazoline-stimulated LC<sub>20</sub> phosphorylation levels were 0.58 ± 0.08 mol P<sub>i</sub>/mol LC<sub>20</sub> at room temperature and 0.49 ± 0.05 mol P<sub>i</sub>/mol LC<sub>20</sub> at 37°C. We conclude, therefore, that the enhanced cirazoline-induced contraction at 37°C is not due to increased LC<sub>20</sub> phosphorylation.

**Keywords:** vascular smooth muscle, contraction, myosin phosphorylation, temperature dependence, cirazoline

**Introduction**

Receptor-operated activation of vascular smooth muscle contraction by various agonists involves mechanisms that elevate cytosolic free Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) through its release from intracellular stores and transmembrane influx from the extracellular fluid (1, 2). A rise in [Ca<sup>2+</sup>]<sub>i</sub> is the most important stimulus for force production in smooth muscle and leads to activation of Ca<sup>2+</sup>/calmodulin (CaM)-dependent myosin light chain kinase (MLCK) and hence phosphorylation of the 20-kDa light chains of myosin (LC<sub>20</sub>) at serine19 (3, 4). This simple phosphorylation reaction triggers cycling of myosin crossbridges along actin filaments and force

development or shortening of the muscle. Myosin phosphorylation is necessary and sufficient for contraction of smooth muscle in general. Relaxation generally follows a return of [Ca<sup>2+</sup>]<sub>i</sub> to resting levels, resulting in dissociation of Ca<sup>2+</sup> from CaM, inactivation of MLCK, and dephosphorylation of myosin catalyzed by myosin light chain phosphatase (MLCP), a myosin-associated type 1 protein serine/threonine phosphatase (5). However, several instances have been reported of dissociation of myosin phosphorylation and force (6–11). Dillon et al. originally described tension maintenance during prolonged stimulation while myosin was dephosphorylated (6) and ascribed this “latch state” to a slow rate of detachment of attached, dephosphorylated crossbridges (12).

We previously investigated the relationship between LC<sub>20</sub> phosphorylation and contraction in de-endothelial-

\*Corresponding author. FAX: +81-424-95-8726

E-mail: mitsuom@my-pharm.ac.jp

ized rat caudal arterial smooth muscle at room temperature (13) and reached the following principal conclusions: i) The contractile response to a sub-maximal concentration of the  $\alpha_1$ -adrenoceptor agonist cirazoline at room temperature is biphasic, consisting of a rapid phasic contraction followed by a sustained tonic contraction; ii) The phasic component of the contraction is due to the release of  $\text{Ca}^{2+}$  from the sarcoplasmic reticulum and the tonic component to the entry of extracellular  $\text{Ca}^{2+}$ ; iii) The time course of  $\text{LC}_{20}$  phosphorylation, which occurs exclusively at serine19, closely parallels that of force, such that force maintenance correlates with high levels of  $\text{LC}_{20}$  phosphorylation catalyzed by MLCK. Therefore, no latch state was detected in this tissue in response to  $\alpha_1$ -adrenoceptor activation at room temperature.

Temperature is an important determinant of membrane fluidity (14, 15) and a critical determinant of myogenic contraction in vascular smooth muscle (16, 17). Moreover, temperature has been shown to affect many stages in the excitation-contraction coupling process: lowering temperature decreases the maximal shortening velocity and the rate of force development (18–23) and slows the rates of phosphorylation and dephosphorylation of myosin by decreasing the activities of both MLCK and MLCP, but with a more potent effect on the latter in chemically skinned smooth muscle (24). This was associated with increased  $\text{LC}_{20}$  phosphorylation and greater force developed by the tissue at lower temperature at the same  $[\text{Ca}^{2+}]_i$  (24). Therefore, we hypothesized that cirazoline-activated  $\text{LC}_{20}$  phosphorylation during force maintenance at room temperature (13) remains high due to the low temperature and therefore low MLCP activity, and increasing the temperature to  $37^\circ\text{C}$  would activate MLCP more than MLCK and, therefore, result in a reduction in  $\text{LC}_{20}$  phosphorylation and force. Hence we compared the relationship between  $\text{LC}_{20}$  phosphorylation and contraction in de-endothelialized rat caudal arterial smooth muscle in response to  $\alpha_1$ -adrenoceptor stimulation at room temperature and  $37^\circ\text{C}$ .

## Materials and Methods

### Materials

Cirazoline was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Dithiothreitol (DTT) was from Wako Pure Chemical Industries, Ltd. (Osaka). Hepes (*N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid) was from Dojindo Laboratories (Kumamoto). BM Chemiluminescence Western Blotting Kit was from Roche (Mannheim, Germany). All other chemicals were of reagent grade.

### Preparation of muscle strips and tension measurement

Male Sprague-Dawley rats (250–450 g) were sacrificed by a blow on the neck and exsanguination as approved by the Institutional Ethics Committee for Animal Research at Meiji Pharmaceutical University. Caudal arterial smooth muscle strips were isolated as previously described (13, 25). The endothelial layer and adventitial tissue were removed mechanically. Helical strips ( $0.5\text{ mm} \times 6\text{--}7\text{ mm}$ ) were cut and stored in Hepes-Tyrode (H-T) solution (137 mM NaCl, 2.7 mM KCl, 1.8 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 5.6 mM glucose, 10 mM Hepes, pH 7.4 at room temperature or  $37^\circ\text{C}$ ). Muscle strips were mounted horizontally between two hooks and immersed in a pool of solution ( $750\ \mu\text{l}$ ), which had a rounded surface, on a rotation plate placed on a temperature-controlled stage. One hook was connected to a force displacement transducer (TB-612T; Nihon Kohden, Tokyo) mounted on a micromanipulator and the other to a second micromanipulator. Solution changes were effected rapidly by rotation of the plate. A resting tension of 75 mg was experimentally determined to give a maximal contractile response to 40 mM KCl and was used for all experiments. Once mounted, muscle strips were held at this resting tension in H-T solution at room temperature ( $23^\circ\text{C}$ ) or  $37^\circ\text{C}$  for 45 min prior to transfer to the test solution. Sequential treatments with cirazoline separated by periods of relaxation elicited identical contractile responses in the same muscle strip. All solutions were bubbled thoroughly with 100%  $\text{O}_2$ .

### Quantification of myosin light chain phosphorylation

Quantification of  $\text{LC}_{20}$  phosphorylation was achieved as previously described (13, 25). Tissue samples were frozen in 10% TCA, 10 mM DTT in dry ice/acetone for 10 min at selected times following agonist stimulation. Frozen muscle strips were then washed with 10 mM DTT in acetone at room temperature. The tissues were lyophilized overnight and stored at  $-80^\circ\text{C}$  until  $\text{LC}_{20}$  extraction. Proteins were extracted from tissue strips in  $30\ \mu\text{l}$  of extraction buffer (6 M deionized urea, 20.1 mM Tris, 22.2 mM glycine, 10 mM DTT, 10 mM EGTA, 1 mM EDTA, 1 mM PMSF, 0.6 M KI and 0.15 mM bromophenol blue) by constant rotation in a microcentrifuge tube for 90 min at room temperature. After filtration and centrifugation, phosphorylated and unphosphorylated  $\text{LC}_{20}$  were separated by urea/glycerol gel electrophoresis and transblotted to a nitrocellulose membrane (BioRad, Mississauga, Ontario, Canada) in 10 mM Na-cyclohexylaminopropanesulfonic acid, pH 11 in a Mini Transblot cell (BioRad) at 27 V and  $5^\circ\text{C}$  for 16 h.  $\text{LC}_{20}$  was detected using a polyclonal antibody raised in rabbits against purified chicken gizzard  $\text{LC}_{20}$  with enhanced chemiluminescence detection (13). Phos-

phorylated and unphosphorylated LC<sub>20</sub> bands were quantified by densitometric scanning with a Pharmacia Image Master Desktop Scanning System using Image Master 1D software with data storage on a Pharmacia Biotech NEC Image 466es equipped with a Sharp JX-330 scanner. LC<sub>20</sub> phosphorylation levels were calculated by dividing the chemiluminescence signal (optical density × area) of the phosphorylated LC<sub>20</sub> peak by the total chemiluminescence signal of the phosphorylated and unphosphorylated LC<sub>20</sub> peaks. We observed no diphosphorylated LC<sub>20</sub> in any experiment, that is, LC<sub>20</sub> phosphorylated at both serine19 and threonine18.

#### Statistical analyses

All statistical analyses were performed using StatView-J5.0 (SAS Institute Inc., Cary, NC, USA). Student's paired or unpaired *t*-tests were performed as appropriate and *P*<0.05 was considered significant. Data represent the mean ± S.E.M. Values of *n* indicate the numbers of strips utilized.


## Results

#### Contractile sensitivity to cirazoline at room temperature and 37°C

Helical strips of de-endothelialized rat caudal arteries contracted in response to the α<sub>1</sub>-adrenoceptor agonist cirazoline in a concentration-dependent manner with EC<sub>50</sub> values of 76.6 ± 18.2 and 14.5 ± 1.9 nM at room temperature (23°C) and 37°C, respectively (Fig. 1). These values are statistically significantly different. The maximal forces developed in response to cirazoline were 471.0 ± 64.1 mg at room temperature and 535.0 ± 47.5 mg at 37°C, respectively, but not significantly different.

#### Time courses of cirazoline-induced contraction at room temperature and 37°C

The contractile response to a sub-maximal concentration (0.3 μM) of cirazoline at room temperature was biphasic (Fig. 2 and Ref. 13): an initial phasic contraction, which peaked 30 s after the addition of cirazoline, was followed by a sustained tonic contraction that reached a plateau approximately 5 min after the addition of cirazoline. On the other hand, the contractile response to 0.3 μM cirazoline at 37°C was monophasic with a sustained tonic contraction (Fig. 2). The contraction at 37°C reached a plateau approximately 6 min after the addition of cirazoline. Maximal force in response to 0.3 μM cirazoline was 263.8 ± 18.4 and 464.6 ± 31.6 mg at room temperature and 37°C, respectively, indicating that 0.3 μM cirazoline-induced maximal force at 37°C was approximately 1.8 times that at room temperature.




**Fig. 1.** Concentration dependence of cirazoline-induced contraction of rat caudal arteries at room temperature and 37°C. De-endothelialized rat caudal arterial smooth muscle strips were held at resting tension for 45 min at room temperature (23°C, open circles) or 37°C (closed circles) and then transferred to solution containing various concentrations of cirazoline. Values represent the mean ± S.E.M. (*n* = 4). \**P*<0.05, \*\**P*<0.005: significantly different from the corresponding values at room temperature by Student's *t*-test. The concentration of cirazoline required to produce 50% of the maximal contraction (EC<sub>50</sub>) was 76.6 ± 18.2 nM at room temperature and 14.5 ± 1.9 nM at 37°C; the difference between these values was statistically significant (*P*<0.05).

#### Quantification of LC<sub>20</sub> phosphorylation in response to cirazoline treatment at room temperature and 37°C

LC<sub>20</sub> phosphorylation (monophosphorylation) levels at 37°C increased rapidly in response to cirazoline from a resting level of 0.09 ± 0.04 mol P<sub>i</sub>/mol LC<sub>20</sub> to a peak and an approximate plateau of 0.47 ± 0.06 mol P<sub>i</sub>/mol LC<sub>20</sub> 30 s after cirazoline addition, and they closely matched the time course of contraction (Fig. 3). LC<sub>20</sub> phosphorylation appeared to decline slightly 1 min after cirazoline addition, but this value was not significantly different from that 30 s after cirazoline addition. Moreover, LC<sub>20</sub> phosphorylation was maintained at this level for at least 15 min in the continued presence of cirazoline with maximal LC<sub>20</sub> phosphorylation stoichiometry of 0.49 ± 0.05 mol P<sub>i</sub>/mol LC<sub>20</sub>. Force maintenance stimulated by 0.3 μM cirazoline at 37°C, therefore, correlates with maintenance of a high level of LC<sub>20</sub> phosphorylation.

LC<sub>20</sub> phosphorylation (monophosphorylation) levels at room temperature also increased rapidly in response to cirazoline from a resting level of 0.22 ± 0.06 mol P<sub>i</sub>/mol LC<sub>20</sub> to a peak of 0.54 ± 0.05 mol P<sub>i</sub>/mol LC<sub>20</sub> 15 s after cirazoline addition (Fig. 4). LC<sub>20</sub> phosphorylation then declined significantly 30 s and

1 min after cirazoline addition, before increasing again to a sustained level of  $0.58 \pm 0.08$  mol  $P_i$ /mol  $LC_{20}$ . We previously reported these results (13). The biphasic contraction followed very closely the change in  $LC_{20}$  phosphorylation and force maintenance correlated with maintenance of this high level of  $LC_{20}$  phosphorylation.



Resting  $LC_{20}$  phosphorylation levels and the time courses of increased  $LC_{20}$  phosphorylation did not differ significantly at room temperature and 37°C (Fig. 4), indicating that cirazoline-stimulated  $LC_{20}$  phosphorylation was unaffected by temperature.


#### Relationship between $LC_{20}$ phosphorylation and force at room temperature and 37°C

From the data of Figs. 2B and 4, the tension- $LC_{20}$  monophosphorylation relationship was determined at room temperature and 37°C. This relationship was shifted to the left with little difference in slope at 37°C compared to room temperature, indicating that greater force is generated at a given level of  $LC_{20}$  phosphorylation at the physiological temperature (Fig. 5).

#### Discussion

The phosphorylation of  $LC_{20}$  triggers the cycling of myosin crossbridges along actin filaments, leading to force development or contraction of smooth muscle. This activation mechanism, however, cannot explain all the regulatory properties of smooth muscle contraction, and dissociation of force and myosin phosphorylation has frequently been observed. Nevertheless, we previously reported that cirazoline-induced  $LC_{20}$  phosphorylation in rat caudal arterial smooth muscle closely matched the time course of contraction at room temperature (13), that is, we detected no latch state (reduction of  $LC_{20}$  phosphorylation during force maintenance (12)). To determine whether the latch state is temperature-dependent, we compared the relationship between  $LC_{20}$  phosphorylation and contraction induced in de-endothelialized rat caudal arterial smooth muscle by cirazoline at room temperature and at physiological temperature. Alterations of temperature are known to


**Fig. 2.** Comparison between contractions in response to cirazoline at room temperature and 37°C. De-endothelialized rat caudal arterial smooth muscle strips were held at resting tension for 45 min at room temperature or 37°C and then transferred to solution containing 0.3  $\mu$ M cirazoline. **A:** A typical trace showing 0.3  $\mu$ M cirazoline (CIR)-induced contraction of rat caudal arterial smooth muscle at room temperature (RT) and 37°C. The trace is representative of four experiments. **B:** Cumulative data showing the contractile responses at room temperature (open circles) and at 37°C (closed circles). **C:** The contractile responses induced by 0.3  $\mu$ M cirazoline are shown on an expanded time scale between 0 and 60 s. Force development was expressed as a percentage of the maximal force developed in response to 0.3  $\mu$ M cirazoline at room temperature. Maximal force in response to 0.3  $\mu$ M cirazoline was  $263.8 \pm 18.4$  and  $464.6 \pm 31.6$  mg at room temperature and 37°C, respectively. Values represent the mean  $\pm$  S.E.M. ( $n = 4$ ). \* $P < 0.05$ , \*\* $P < 0.005$ : significantly different from the value for the contractile response at room temperature by Student's  $t$ -test.




**Fig. 3.** Contraction and myosin light chain phosphorylation (mono-phosphorylation) in response to cirazoline treatment at 37°C. De-endothelialized rat caudal arterial smooth muscle strips were held at resting tension for 45 min and then transferred to solution containing 0.3  $\mu$ M cirazoline at 37°C. Tissues were frozen at the indicated times and LC<sub>20</sub> phosphorylation was quantified, as described in the Materials and Methods section. A: Representative Western blots showing separation of phosphorylated (P-LC<sub>20</sub>) and unphosphorylated LC<sub>20</sub> (LC<sub>20</sub>) by urea/glycerol gel electrophoresis. Lane 1: resting conditions at 37°C. Lanes 2–7: 15 s, 30 s, 1 min, 2 min, 5 min, and 15 min, respectively, following addition of cirazoline. B: The time courses of force development (closed circles, expressed as a percentage of the maximal force developed in response to 0.3  $\mu$ M cirazoline at 37°C) and LC<sub>20</sub> phosphorylation (closed squares, expressed as mol P<sub>i</sub>/mol LC<sub>20</sub>) were quantified. Values represent the mean  $\pm$  S.E.M. (n = 4 for force and phosphorylation data). Maximal force was 476.0  $\pm$  34.5 mg. Resting and maximal LC<sub>20</sub> phosphorylation levels were 0.09  $\pm$  0.04 and 0.49  $\pm$  0.05 mol P<sub>i</sub>/mol LC<sub>20</sub>, respectively.

have a strong modulatory influence on the mechanical activity of different types of smooth muscle. However, there is little definitive information concerning the fundamental mechanisms underlying the effect of changes in temperature, which vary considerably between different smooth muscles. In intact smooth muscles, lowering temperature was reported to have both potentiating (24, 26–28) and inhibitory effects (18, 20, 29, 30), depending on the method of stimulation, experimental conditions (31, 32), and species (19, 23).

In rat caudal arterial smooth muscle, the concentration-response relationship of contraction induced by cirazoline at 37°C was shifted to the left as compared



**Fig. 4.** Time courses of myosin light chain phosphorylation (monophosphorylation) in response to cirazoline treatment at room temperature and 37°C. De-endothelialized rat caudal arterial smooth muscle strips were held at resting tension for 45 min and then transferred to solution containing 0.3  $\mu$ M cirazoline at room temperature or 37°C. Tissues were frozen at the indicated times and LC<sub>20</sub> phosphorylation was quantified [n = 3 for the results at room temperature (open squares) and n = 4 for the results at 37°C (closed squares)]. Values are expressed as mol P<sub>i</sub>/mol LC<sub>20</sub> and represent the mean  $\pm$  S.E.M. The LC<sub>20</sub> phosphorylation data at 37°C are the same as shown in Fig. 3. Resting and maximal LC<sub>20</sub> phosphorylation levels were 0.22  $\pm$  0.06 and 0.58  $\pm$  0.08 mol P<sub>i</sub>/mol LC<sub>20</sub> at room temperature and 0.09  $\pm$  0.04 and 0.49  $\pm$  0.05 mol P<sub>i</sub>/mol LC<sub>20</sub> at 37°C, respectively. The values at room temperature and 37°C were not statistically significantly different.



**Fig. 5.** Relationships between contraction and myosin light chain phosphorylation (monophosphorylation) in response to cirazoline treatment at room temperature and 37°C. From the data in Figs. 2B and 4, the relationships between tension and LC<sub>20</sub> monophosphorylation were determined at room temperature (open triangle) and at 37°C (closed triangle). Tension in response to 0.3  $\mu$ M cirazoline treatment was expressed in mg and phosphorylated LC<sub>20</sub> was expressed as a percentage of the total LC<sub>20</sub>. Values represent the mean  $\pm$  S.E.M. (n = 4).

with that at room temperature (Fig. 1), indicating that the sensitivity to cirazoline is affected by the change in temperature. Furthermore, cirazoline-induced maximal force at 37°C was approximately 1.8 times that at room temperature (Fig. 2). However, the initial rate of force development at 37°C was similar to that at room temperature (Fig. 2C), indicating that the rate of contraction was temperature insensitive.

The time course of LC<sub>20</sub> monophosphorylation, which occurred exclusively at serine19 (13), closely paralleled that of force at both room temperature and 37°C. Furthermore, force maintenance correlated with maintenance of high levels of LC<sub>20</sub> monophosphorylation at both temperatures (Fig. 4), that is, we obtained no evidence for formation of a latch state either at room temperature or at 37°C. Moreover, the tension-LC<sub>20</sub> monophosphorylation relationship was shifted to the left at 37°C with little difference in the slope of the relationship (Fig. 5). *In vitro* studies have indicated that MLCK and MLCP exhibit very different temperature dependencies. MLCP has an unusually high Q<sub>10</sub> (5.2) compared to that of MLCK (1.7) (24). This would suggest that increasing the temperature from 23°C to 37°C would decrease LC<sub>20</sub> phosphorylation, resulting in a decrease in the rate of contraction and/or steady-state force generated. The rate of contraction, however, was found to be similar at each temperature and steady-state force was significantly greater at 37°C (Fig. 2). Our results suggest that the anticipated greater increase in MLCP activity than that of MLCK in going from 23°C to 37°C is balanced by enhanced inhibition of MLCP at the higher temperature by the protein kinase C (PKC)/CPI-17 pathway and/or the RhoA/Rho-associated kinase pathway (2). The fact that the time courses of LC<sub>20</sub> phosphorylation were quantitatively similar at the two temperatures (Fig. 4) is consistent with the similar rates of contraction, and indicates that the greater steady-state force at 37°C is not due to an increase in LC<sub>20</sub> phosphorylation stoichiometry.

The thin filament-associated proteins calponin and caldesmon could account for the augmentation of force at the higher temperature. Calponin colocalizes with actin and tropomyosin in smooth muscle and inhibits the actin-activated Mg<sup>2+</sup>-ATPase activity of phosphorylated smooth muscle myosin (33). Actin binding and ATPase inhibition are alleviated by phosphorylation of calponin by PKC or Ca<sup>2+</sup>/CaM-dependent protein kinase II (3). Caldesmon, which is expressed in smooth muscle and nonmuscle cells and is also localized to actin filaments, has also been implicated in the regulation of crossbridge cycling (34). It has been shown to inhibit actomyosin ATPase activity and the movement of actin filaments over phosphorylated myosin in the *in vitro* motility

assay. Pfitzer et al. (35) previously reported that addition of caldesmon to chemically skinned smooth muscle strips causes a rightward shift in the force-LC<sub>20</sub> phosphorylation relationship. Caldesmon is phosphorylated by the mitogen-activated protein kinase, which reduces its affinity for actin, leading to loss of inhibition of the actomyosin ATPase and contraction (36). Enhanced phosphorylation of calponin and caldesmon could, therefore, explain the increased steady-state force at 37°C in response to cirazoline treatment. We previously attributed the plateau phase of cirazoline-induced contraction to maintained Ca<sup>2+</sup> entry via voltage-gated Ca<sup>2+</sup> channels since it was abolished by removal of extracellular Ca<sup>2+</sup> or treatment with the L-type Ca<sup>2+</sup> channel blocker nifedipine (13). Burdyga and Wray (18, 19) demonstrated that in guinea-pig and rat ureteric smooth muscles, the rate of rise or amplitude of the Ca<sup>2+</sup> transient are little influenced by temperature and do not underlie its effects on force, suggesting that temperature does not affect Ca<sup>2+</sup> entry through L-type Ca<sup>2+</sup> channels from the extracellular space or Ca<sup>2+</sup> release from the sarcoplasmic reticulum. However, it may not be possible to extrapolate from these species and phasic smooth muscle tissues to the tonic rat caudal artery. Increased temperature might, therefore, enhance Ca<sup>2+</sup> entry during the sustained phase of contraction of the rat caudal artery, leading to an increase in MLCK activity. Since Ca<sup>2+</sup>-dependent myosin phosphorylation during the sustained contraction is comparable at room temperature and 37°C, the increase in MLCK activity would have to be balanced by a greater increase in MLCP activity at the higher temperature. However, the fact that augmentation of  $\alpha_1$ -adrenoceptor-mediated contraction by warming occurs without increased LC<sub>20</sub> phosphorylation, it is necessary to consider factors other than Ca<sup>2+</sup> dependency, in particular, Ca<sup>2+</sup>-insensitive mechanisms of force production. We conclude, therefore, that the augmentation of force induced by cirazoline at higher temperature may be attributed to Ca<sup>2+</sup>-insensitive mechanisms involved in force production such as calponin or caldesmon phosphorylation.

### Acknowledgments

We are very grateful to Cindy Sutherland for expert technical assistance. This work was supported by a special grant from Meiji Pharmaceutical University to M.M. and by a grant (MOP-13101) to M.P.W. from the Canadian Institutes of Health Research (CIHR). M.P.W. is an Alberta Heritage Foundation for Medical Research Scientist, holder of a Canada Research Chair (Tier I) in Biochemistry, and Director of the CIHR Group in Regulation of Vascular Contractility.

## References

- 1 Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. *Nature*. 1994;372:231–236.
- 2 Somlyo AP, Somlyo AV.  $\text{Ca}^{2+}$  sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases and myosin phosphatase. *Physiol Rev*. 2003;83:1325–1358.
- 3 Allen BG, Walsh MP. The biochemical basis of the regulation of smooth-muscle contraction. *Trends Biochem Sci*. 1994;19:362–368.
- 4 Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. *J Biol Chem*. 2001;276:4527–4530.
- 5 Hartshorne DJ, Ito M, Erdödi F. Role of protein phosphatase type 1 in contractile functions: myosin phosphatase. *J Biol Chem*. 2004;279:37211–37214.
- 6 Dillon PF, Aksoy MO, Driska SP, Murphy RA. Myosin phosphorylation and the cross-bridge cycle in arterial smooth muscle. *Science*. 1981;211:495–497.
- 7 Rembold CM, Murphy RA. Myoplasmic  $[\text{Ca}^{2+}]$  determines myosin phosphorylation in agonist-stimulated swine arterial smooth muscle. *Circ Res*. 1988;63:593–603.
- 8 Jiang MJ, Morgan KG. Agonist-specific myosin phosphorylation and intracellular calcium during isometric contractions of arterial smooth muscle. *Pflugers Arch*. 1989;413:637–643.
- 9 Tansey MG, Hori M, Karaki H, Kamm KE, Stull JT. Okadaic acid uncouples myosin light chain phosphorylation and tension in smooth muscle. *FEBS Lett*. 1990;270:219–221.
- 10 Suematsu E, Resnick M, Morgan KG. Change of  $\text{Ca}^{2+}$  requirement for myosin phosphorylation by prostaglandin  $\text{F}_{2\alpha}$ . *Am J Physiol*. 1991;261:C253–C258.
- 11 Gunst SJ, Al-Hassani MH, Adam LP. Regulation of isotonic shortening velocity by second messengers in tracheal smooth muscle. *Am J Physiol*. 1994;266:C684–C691.
- 12 Hai C-M, Murphy RA.  $\text{Ca}^{2+}$ , crossbridge phosphorylation, and contraction. *Annu Rev Physiol*. 1989;51:285–298.
- 13 Mita M, Walsh MP.  $\alpha_1$ -Adrenoceptor-mediated phosphorylation of myosin in rat-tail arterial smooth muscle. *Biochem J*. 1997;327:669–674.
- 14 Blazyk J, Wu CJ, Wu SC. Correlation between lipid fluidity and tryptic susceptibility of  $\text{Ca}^{2+}$ -ATPase in sarcoplasmic reticulum membrane. *J Biol Chem*. 1985;260:4845–4849.
- 15 Rubtsov AM, Sentjure M, Schara M. Effect of temperature on Ca-ATPase from sarcoplasmic reticulum membrane: ESR studies. *Gen Physiol Biophys*. 1986;5:551–561.
- 16 Laher I, Van Breemen C, Bevan JA. Stretch-dependent calcium uptake associated with myogenic tone in rabbit facial vein. *Circ Res*. 1988;63:669–672.
- 17 Tanaka Y, Hata S, Ishiro H, Nakayama K. Stretching releases  $\text{Ca}^{2+}$  from intracellular storage sites in canine cerebral arteries. *Can J Physiol Pharmacol*. 1994;72:19–24.
- 18 Burdya TV, Wray S. The relationship between the action potential, intracellular calcium and force in intact phasic, guinea-pig ureteric smooth muscle. *J Physiol (Lond)*. 1999;520:867–883.
- 19 Burdya TV, Wray S. On the mechanisms whereby temperature affects excitation-contraction coupling in smooth muscle. *J Gen Physiol*. 2002;119:93–104.
- 20 Stephens N, Cardinal R, Simmons B. Mechanical properties of tracheal smooth muscle: effects of temperature. *Am J Physiol*. 1977;233:C92–C98.
- 21 Klemt P, Peiper U. The dynamics of cross-bridge movement in vascular smooth muscle estimated from a single isometric contraction of the portal vein: the influence of temperature. *Pflugers Arch*. 1978;378:31–36.
- 22 Paul RJ, Doerman G, Zeugner C, Ruegg JC. The dependence of unloaded shortening velocity on  $\text{Ca}^{2+}$ , calmodulin, and duration of contraction in “chemically skinned” smooth muscle. *Circ Res*. 1983;53:342–351.
- 23 Burdya TV, Magura IS. The effects of local anaesthetics on the electrical and mechanical activity of the guinea-pig ureter. *Br J Pharmacol*. 1986;88:523–530.
- 24 Mitsui T, Kitazawa T, Ikebe M. Correlation between high temperature dependence of smooth muscle myosin light chain phosphatase activity and muscle relaxation rate. *J Biol Chem*. 1994;269:5842–5848.
- 25 Mita M, Yanagihara H, Hishinuma S, Saito M, Walsh MP. Membrane depolarization-induced contraction of rat caudal arterial smooth muscle involves Rho-associated kinase. *Biochem J*. 2002;364:431–440.
- 26 Webb-Peploe MM, Shepherd JT. Peripheral mechanisms involved in response of dog’s cutaneous veins to local temperature changes. *Circ Res*. 1968;23:701–708.
- 27 Vanhoutte PM, Lorenz RR. Effect of temperature on reactivity of saphenous, mesenteric, and femoral veins of the dog. *Am J Physiol*. 1970;218:1746–1750.
- 28 Bratton DL, Tanaka DT, Grunstein MM. Effects of temperature on cholinergic contractility of rabbit airway smooth muscle. *J Appl Physiol*. 1987;63:1933–1941.
- 29 Godfraind T, Kaba A. The role of calcium in the action of drugs on vascular smooth muscle. *Arch Int Pharmacodyn Ther*. 1972;196 Suppl:35.
- 30 Kawarai R, Chiba S. Different sensitivity changes of canine and simian femoral arterial and venous constrictions by cooling. *Jpn J Pharmacol*. 1989;49:544–548.
- 31 Sabeur G. Effect of temperature on the contractile response of isolated rat small intestine to acetylcholine and KCl: calcium dependence. *Arch Physiol Biochem*. 1996;104:220–228.
- 32 Vanhoutte PM, Corcaud S, de Montrion C. Venous disease: from pathophysiology to quality of life. *Angiology*. 1997;48:559–567.
- 33 Winder SJ, Walsh MP. Calponin: thin filament-linked regulation of smooth muscle contraction. *Cell Signal*. 1993;5:677–686.
- 34 Sobue K, Sellers JR. Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems. *J Biol Chem*. 1991;266:12115–12118.
- 35 Pfitzer G, Zeugner C, Troschka M, Chalovich JM. Caldesmon and a 20-kDa actin-binding fragment of caldesmon inhibit tension development in skinned gizzard muscle fiber bundles. *Proc Natl Acad Sci U S A*. 1993;90:5904–5908.
- 36 Adam LP, Hathaway DR. Identification of mitogen-activated protein kinase phosphorylation sequences in mammalian h-caldesmon. *FEBS Lett*. 1993;322:56–60.